Wet Macular Degeneration: Symptoms, Injections, Outlook and Integrative Support

Wet macular degeneration (wet AMD) is one of the two late forms of age-related macular degeneration. Abnormal blood vessels grow under the retina and leak fluid or blood into the macula, the small central area you use for reading and recognizing faces^1,2,3,4. It usually causes faster vision loss than the dry form¹. The first sign is often straight lines that look wavy, or a blurry or dark patch in the center of your vision¹. If you notice these signs, call an eye doctor the same day and ask to be seen within a day or two^1,5. Anti-VEGF eye injections are the main treatment. They slow or stop vision loss, and in trials many people gained vision in the first year^4,6,7. Wet AMD is controlled, not cured: most people need injections for years, and it often becomes active again if they stop^8,9. It does not cause complete blindness, because side vision is spared^1,10.

This page goes deeper on wet AMD than our macular degeneration guide, which covers both types.

Wet AMD at a glance

On this page

• What is wet AMD?
• How common is it?
• Symptoms and when to be seen
• Who gets wet AMD?
• Diagnosis and home monitoring
• Treatment
• Stopping injections
• Can it be reversed?
• New treatments in clinical trials
• Living with wet AMD
• Where integrative care fits
• Outlook
• Frequently asked questions
• Sources

What is wet macular degeneration?

AMD damages the macula, the center of the retina¹. Most people with AMD have dry AMD, in which the macula thins slowly over years. Any stage of dry AMD can turn into wet AMD, and wet AMD is always a late stage¹. It happens when the eye makes too much of a protein called vascular endothelial growth factor (VEGF), which makes abnormal blood vessels grow and leak^4,8. The fluid and blood damage the macula^1,2. Its formal names, exudative or neovascular AMD, refer to the leaking fluid and the new vessels¹⁵.

Doctors call the abnormal vessels macular neovascularization (MNV). Type 1 grows under the retina's pigment layer, type 2 grows through that layer into the space under the retina, and type 3 grows down from the retina's own blood vessels²⁰. Polypoidal choroidal vasculopathy (PCV) is a form of type 1 with bulging, polyp-like vessels that bleed easily. It is a minority form in white populations but accounts for about half of wet AMD in people in Asia, and it can need a different treatment plan²⁰.

Wet and dry AMD can occur together. Areas of thinning and cell loss (atrophy) can develop over the years in eyes with wet AMD, whether or not they are treated^21,22.

How common is wet AMD?

• Age is the strongest factor. In pooled studies of mostly white people in the US, Europe and Australia, wet AMD affected about 1 in 600 people aged 55 to 64 and about 1 in 17 people over 85¹³.
• In the US, about 1.5 million people aged 40 and older had late AMD, wet or dry, in 2019³. Worldwide, wet AMD and late dry AMD (geographic atrophy) are about equally common²³.
• Vision loss. In a 1984 report on two groups of patients, from before today's treatments, 79% and 90% of eyes that were legally blind from AMD had wet AMD¹¹.

Symptoms of wet macular degeneration

Common symptoms are^1,15,5:

• straight lines, such as door frames or lines of text, that look wavy or bent;
• a blurry, gray or dark patch in the center of your vision that can grow;
• objects that look smaller than they are;
• colors that look less bright, and more trouble seeing in dim light.

Wet AMD is painless¹⁵. If only one eye is affected, you may not notice at first, so check each eye on its own. When wet AMD comes back after treatment, many people notice nothing: in a Swedish study, only 41% of people whose disease returned had symptoms²⁴. That is why regular scans matter.

How quickly to be seen

New wavy lines or a new blurry or dark patch are warning signs. Call your eye doctor the same day, ideally a retina specialist, and do not wait for your next routine visit or your next injection^1,5. In the UK, national guidance says people with suspected wet AMD should be referred within one working day and treated within 14 days⁵. Delay can cost vision: in a German study of 69 people, about 1 in 11 lost a line or more on the eye chart within 3 weeks of diagnosis, before treatment started²⁵.

Who gets wet AMD?

• Age. Risk rises steeply after 55^1,13.
• Smoking is the main risk you can change¹³. Current smokers have two to three times the risk of AMD²⁶. People who had quit for more than 20 years had a risk similar to people who never smoked²⁷. Smokers on injections also gained less vision in the first year (3.5 letters, against 7.7 in non-smokers)²⁸.
• Family history and genes. Close relatives of people with AMD were about twice as likely to have it, and common variants in two genes, ARMS2 and CFH, raise the risk of wet AMD^29,30. Genetic testing is not recommended, because the results cannot guide prevention or treatment³¹.
• Ancestry. Wet AMD is more common in white people of European ancestry, and PCV in people of Asian ancestry^32,23,20.
• Other factors linked to late AMD include a higher body mass index, heart and blood vessel disease, high blood pressure and past cataract surgery³³. A Mediterranean-style diet was linked to a 16% lower risk of progressing to wet AMD in an observational analysis³⁴.

When dry AMD turns wet. Your eye doctor can estimate your risk from the size of the yellow deposits (drusen) and pigment changes in both eyes. In the AREDS study, the five-year risk of late AMD (wet AMD or advanced dry AMD) ranged from 0.5% with none of these signs to 50% with large drusen and pigment changes in both eyes³⁵.

The other eye. Once one eye has wet AMD, the other eye is at higher risk¹. Wet AMD developed in the second eye in about 1 in 6 to 1 in 5 people within two years in a large US trial, and in about 1 in 3 (32%) in a large London clinic^36,37. In that clinic, second eyes started treatment with better vision than first eyes had, one reason both eyes are checked at every visit³⁷.

How wet AMD is diagnosed

Wet AMD is found during a dilated eye exam¹.

• Optical coherence tomography (OCT) is a quick, painless scan that shows the layers of the retina and any fluid under or within it. It is the main test for diagnosis and follow-up, and both eyes are scanned at follow-up visits^5,1.
• Fluorescein angiography uses a dye injected into the arm to photograph the retina's blood vessels. It is used when OCT cannot rule out wet AMD⁵.
• Indocyanine green angiography uses a different dye and is one of the best tests for PCV^20,38.
• OCT angiography shows abnormal vessels without dye. In pooled studies it found about 9 in 10 cases³⁹.

Monitoring at home

• Amsler grid. Your eye doctor may ask you to check each eye every day with this printed grid of straight lines and to call right away if the lines look wavy^40,41. It misses about 1 in 3 cases of wet AMD, so it does not replace regular exams⁴².
• ForeseeHome, a home vision-testing device cleared by the FDA in 2009, helped find wet AMD earlier in a trial of 1,520 people at high risk: users had lost a median of 4 letters when it was found, against 9 with usual care^43,41.
• The Notal Vision Home OCT, a prescription home scanner, was authorized by the FDA in May 2024 for people already diagnosed with wet AMD, for scans between clinic visits. It is not meant to be used for treatment decisions or to replace clinic visits^43,44.

Wet AMD treatment

Anti-VEGF eye injections

Anti-VEGF injections are the main treatment, and most people with wet AMD need no other⁴. The medicine blocks VEGF, which helps stop the bleeding and leaking⁴. It is injected into the eye with a very fine needle, after numbing drops and an antiseptic to clean the eye^45,8. Most people go back to normal activities the same day, but do not drive until your vision has cleared, so plan for someone to drive you home^8,17. The eye may feel irritated from the antiseptic, and you may see floating air bubbles for a day or two⁸. In one study, people rated the pain at about 3 out of 10 on average, and it became less with each injection⁴⁵.

FDA-approved anti-VEGF medicines for wet AMD

Some people need injections more often than the usual schedule, for example monthly^17,53.

Biosimilars and bevacizumab. Ten biosimilars, lower-cost near-copies, were approved from 2021 to 2026: four of Lucentis and six of Eylea⁴⁶. A Cochrane review found little or no difference between biosimilars and the original medicines⁵⁵. Bevacizumab (Avastin), a cancer medicine, is also widely used off-label for wet AMD⁵⁶. In US and UK trials it worked as well as ranibizumab^57,58. One trial found slightly more hospital admissions with bevacizumab, but a review of nine trials could not find a clear difference in serious side effects^57,59.

What injections achieve. In the main trials, people treated regularly gained on average about 5 to 11 letters on the eye chart (one to two lines) in the first year, while eyes given sham (dummy) injections lost about 10 letters^{6,7,60,61,62,63}. About a third to two-fifths of people given monthly ranibizumab gained 15 letters (three lines) or more^6,7. Newer medicines matched aflibercept with fewer injections: with Vabysmo, 59% to 67% of people were on injections every 16 weeks by the end of the second year, and with Eylea HD people needed about 3 to 4 injections in the second year, against nearly 6 with standard Eylea^64,17.

How often injections are given

Almost everyone starts with monthly injections. After that, your retina specialist decides how often you need them, based on your scans and vision^4,8.

• Fixed schedules, such as monthly or every 8 weeks, were used in the main trials and mean frequent visits^6,60.
• As needed: a check-up and scan every month, with an injection only when the scan shows fluid. This gave slightly less vision, about 2 letters on average, than monthly injections^65,66,58.
• Treat and extend: an injection at every visit, with the gap lengthened step by step while the retina stays dry and shortened if fluid returns. In trials, vision was similar to monthly injections with fewer injections, though the evidence is less certain^65,67.

Outside trials, people often get fewer injections and gain less. In a large US records study, people had an average of 7.3 injections in the first year and gained about 1 letter, and those who had more injections tended to gain more⁶⁸. Over 10 years, people who stayed in care had about 40 to 60 injections; in one study, the group that had more injections kept more vision^69,70,71.

Risks of injections

Serious problems are rare.

• Eye infection (endophthalmitis): about 1 in 2,000 to 1 in 3,000 injections in US studies^72,73.
• Retinal detachment: about 1 in 7,500 injections⁷⁴.
• Eye pressure can rise within an hour of an injection and, in some people, stay raised after repeated injections¹⁷.
• Inflammation inside the eye, including inflammation of the retina's blood vessels. This is best known with Beovu: about 4% to 5% of people in its main trials, and 9% of people given it every 4 weeks, more often than the label allows, in a later trial. It has also been reported with Vabysmo and Eylea^{75,76,49,53,48}.
• Blood clots such as stroke or heart attack were reported in small numbers in the trials¹⁷.

Get care right away if, in the days after an injection, your eye becomes more painful or red, is sensitive to light, or your vision gets worse, or if you see new floaters, flashes or a dark curtain. Call your retina practice, or go to an emergency eye service if you cannot reach them. These can be signs of infection, inflammation or a detached retina^8,17,49. Injections are usually given without stopping blood thinners; do not stop or change one on your own⁷⁷.

Photodynamic therapy and polypoidal disease

Photodynamic therapy (PDT) uses a light-sensitive drug, verteporfin, given through a vein and then activated in the eye with a low-energy laser. Afterward you must avoid direct sunlight and bright indoor light for 5 days⁷⁸. Injections largely replaced it: in a direct trial, eyes treated with ranibizumab gained 11.3 letters on average in the first year, while eyes treated with PDT lost 9.5^7,4.

PDT still has a role in PCV. In a trial of 322 people in Asia, adding PDT to ranibizumab gave more vision after two years (9.6 against 5.5 letters gained) and closed the polyps more often, with half as many injections⁷⁹. In another trial, most people with PCV did well on aflibercept alone, and few needed PDT⁸⁰.

Other treatments

• A large bleed under the macula can cause a sudden, large dark patch or a sudden drop in vision. Call your retina specialist the same day, or go to an emergency eye service; treatment works best when it starts within days^81,82. Options include injections with a gas bubble or a clot-dissolving drug to move the blood, or surgery. In a French trial, surgery was not better than gas and injections at three months, and the best approach is not yet known^81,82. If you take a blood thinner, do not stop it unless the doctor who prescribed it tells you to⁸³.
• AREDS2 vitamins for the other eye. If you have late AMD in one eye, the AREDS2 formula may slow AMD in the other eye. It does not treat the wet eye, and if both eyes already have late AMD it probably will not help. If you smoke or used to smoke, choose AREDS2, which has no beta-carotene, because beta-carotene raises the risk of lung cancer^84,85,86. See our guide to macular degeneration vitamins and diet.
• Low vision rehabilitation helps people make the most of the vision they have. In trials in US veterans, it improved everyday visual function and reading speed, and people on a waiting list got worse while they waited, so it is worth starting early^87,88,5.

Can you stop wet AMD injections?

Some people can eventually stop, but others need to keep having injections to protect their vision⁸. Stopping should be tried only with your retina specialist, with regular scans.

• Wet AMD often comes back. In eyes where treatment was paused after three months without activity, it returned in 41% within a year and 79% within five years. Eyes whose disease came back lost some vision, and most did not get all of it back after injections restarted⁹. In a Swedish study, it returned in 53% within a year of the last injection²⁴.
• Missed visits cost vision. Eyes with a gap of more than six months lost vision that had not recovered about a year after treatment restarted⁸⁹. A gap of 6 to 12 months cost about 5 letters on average⁹⁰.
• Many people drop out. In one large US retina practice, more than 1 in 5 people on injections (22%) had no follow-up visit for 12 months⁹¹.

Read more in what happens if you stop eye injections for macular degeneration.

Can wet macular degeneration be reversed?

No, but it can be controlled. Injections can dry the retina, and in the main trials vision improved in the first year by one to two lines on average, and more in some people^6,7,12. Outside trials, gains are often smaller⁶⁸. That is control, not repair. The vessels can become active again, which is why monitoring continues for years^8,9. Scarring and atrophy of the macula do not reverse; in long-term studies, atrophy and scarring were the main causes of vision loss in treated eyes^69,70. Gains often fade with time: in the large US trial, average vision at five years was 3 letters below where it started¹⁶.

New treatments for wet AMD in clinical trials

The aim of current research is fewer injections, or none. None of the treatments below is approved yet. Status is as posted on ClinicalTrials.gov or announced by the companies, checked on October 20, 2026; company results have not yet been published in journals.

No eye drop or pill is approved for wet AMD; a few eye drops are in early trials¹⁹. There have also been setbacks. Duravyu (vorolanib insert; EyePoint) missed its main goal in both phase 3 trials, in August and October 2026, and the company is ending its wet AMD trials early⁹⁷. Sozinibercept, an add-on injection, failed two phase 3 trials in 2025¹⁹. If you are interested in a trial, ask your retina specialist.

Living with wet AMD

• Keep every appointment, even when your vision feels stable^5,89.
• Check each eye at home the way your retina specialist recommends. If you see new wavy lines or a new dark patch, call them the same day; do not wait for your next injection visit^1,41,40.
• Ask your eye doctor whether it is safe for you to drive⁹⁸.
• Tell your retina team about all herbs and supplements. Ginkgo can raise the risk of bleeding with blood thinners, and some highly absorbed curcumin products can harm the liver^99,100.
• Our guide to living with AMD has practical tips.

Where integrative care fits

Netra Eye Institute is an acupuncture and Oriental medicine practice. Nothing we offer replaces anti-VEGF injections, monitoring scans or any other treatment from your retina specialist, and wet AMD care stays with them. Our role is adjunctive: care that sits alongside theirs, with the evidence explained before you start.

The evidence for integrative approaches in wet AMD is weak. We found no published trial that has tested acupuncture alongside anti-VEGF injections, and there is no evidence that acupuncture treats wet AMD or reduces the need for injections^101,102. In a 2023 review, the small trials of acupuncture in wet AMD, all from China, found no clear difference in vision, and the evidence for AMD overall was rated low to very low certainty¹⁰¹. Later reviews also found no conclusive evidence^103,104.

Grades show how sure we can be. Moderate: large, well-run trials. Low: small trials, so the result could easily change. Very low: very small or flawed studies, so we cannot tell. None: no studies. These grades are our own reading of the research.

Acupuncture near the eye carries rare but serious risks: 14 published case reports describe eye injuries¹¹². Tell any acupuncturist if you take a blood thinner.

What working with Netra looks like. We ask first that a retina specialist is managing your wet AMD, with a plan for injections and scans. If you notice new distortion or a new dark patch, call them first; that comes before anything we do. Then we:

• ask whether the basics are in place: your injection and scan schedule, AREDS2 vitamins if your specialist recommends them, not smoking, and blood pressure care with your physician;
• offer acupuncture if you choose it, with its limited evidence explained, and review your blood thinners and other medicines first;
• where appropriate, offer Chinese herbal medicine reviewed against your blood thinners and other medicines;
• never put herbal washes or drops in the eye, and follow your retina specialist's advice around injections;
• keep your eye doctor informed, and urge you to call them right away if you notice any change in your vision.

Netra Restoration Therapy (NRT) is an adjunctive program: it is used only alongside your retina specialist's care, never instead of it. It is not a treatment for wet AMD. It does not replace injections, it does not close abnormal blood vessels, and it has not been shown to reduce the number of injections you need. No clinical trial of NRT in wet AMD has been published. For Ayurvedic approaches, see Ayurvedic treatment for macular degeneration.

Outlook

The outlook for wet AMD has changed greatly since injections arrived. In Denmark, new cases of legal blindness from AMD halved between 2000 and 2010, mostly after injections began in 2006¹¹³.

• At five years, about half of treated eyes checked saw 20/40 or better in a large US trial and in the AREDS2 study, while about 1 in 7 to 1 in 5 saw 20/200 or worse^16,114.
• At ten years, about a third to two-fifths of eyes still treated saw 20/40 or better, and in most of these studies average vision was close to where it started. These studies include only people who stayed in care^69,71,70.

The best results come from starting treatment promptly and keeping up with it^25,89,70.

Life expectancy. Wet AMD itself has not been shown to shorten life. Studies link late AMD with a slightly higher risk of death, which researchers think may reflect links with heart and blood vessel disease^115,116. In a Danish study, people treated with injections did not have a higher risk of death than people without wet AMD¹¹⁷.

Frequently asked questions

Can wet macular degeneration be reversed or cured?

No. It cannot be cured or reversed, but it can be controlled. Injections can dry the retina, and in the main trials vision improved by one to two lines on average in the first year^6,7. Scarring and atrophy do not reverse^69,70, and the disease often becomes active again if injections stop⁹.

What is the newest treatment for wet macular degeneration?

The newest approval is Lytenava, an eye-specific version of bevacizumab (the medicine in Avastin), approved by the FDA in July 2026 and due to launch in the US by the end of 2026⁵⁴. Since April 2026, Eylea HD can be given as far apart as every 20 weeks after a year of good response¹⁷. Newer long-acting treatments and one-time gene therapies are still in trials^19,92,93.

What should you avoid if you have wet macular degeneration?

Do not delay, skip or stretch out injections without your retina specialist's advice; vision lost during long gaps often does not fully come back^9,89. Do not smoke^26,28. Call your eye doctor the same day about new distortion or a dark patch^1,5. Do not stop a prescribed blood thinner on your own; injections are usually given without stopping it⁷⁷.

What is the difference between wet and dry macular degeneration?

Dry AMD is a slow thinning of the macula. Wet AMD is a late form in which abnormal vessels leak fluid or blood. It is less common but causes faster vision loss¹.

Can dry macular degeneration turn into wet?

Yes, at any stage. The risk depends on drusen and pigment changes, which your eye doctor can assess^1,35.

How quickly does wet macular degeneration progress?

It can take vision within weeks. In one study, about 1 in 11 people lost a line or more within 3 weeks while waiting for treatment²⁵.

Do eye injections for wet AMD hurt?

Usually only a little. In one study, pain averaged about 3 out of 10, and it lessened with each injection⁴⁵.

Is wet macular degeneration hereditary?

Genes and family history raise the risk, but genetic testing is not recommended because it cannot guide prevention or treatment^29,30,31.

Are there eye drops for wet macular degeneration?

No. No eye drop is approved; a few are in early trials¹⁹.

Does red light therapy help wet macular degeneration?

No. The only FDA-authorized device is for dry AMD and is not for people with wet AMD¹¹¹.

Can acupuncture help wet macular degeneration?

No trial shows that it treats wet AMD or reduces the need for injections¹⁰¹. Netra offers acupuncture only as adjunctive care alongside your retina specialist, with the evidence explained.

Sources

1. National Eye Institute. Age-Related Macular Degeneration (AMD). Updated June 22, 2021. link
2. MedlinePlus (National Library of Medicine). Macular Degeneration (health topic summary). Updated October 12, 2024. link
3. Rein DB, et al. Prevalence of Age-Related Macular Degeneration in the US in 2019. JAMA Ophthalmol. 2022. link
4. National Eye Institute. Treatments for Wet AMD (Advanced Neovascular AMD). Updated December 5, 2024. link
5. National Institute for Health and Care Excellence. Age-related macular degeneration (NICE guideline NG82): recommendations. January 23, 2018. link
6. Rosenfeld PJ, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006. link
7. Brown DM, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006. link
8. National Eye Institute. Injections to Treat Eye Conditions. Updated March 24, 2026. link
9. Nguyen V, et al. Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months. Ophthalmol Retina. 2019. link
10. Arnold JJ. Age-related macular degeneration: anti-vascular endothelial growth factor treatment. BMJ Clin Evid. 2016. link
11. Ferris FL 3rd, et al. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984. link
12. Solomon SD, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019. link
13. Smith W, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology. 2001. link
14. Klein R, et al. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007. link
15. Cleveland Clinic. Wet Macular Degeneration. Updated September 28, 2023. link
16. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Maguire MG, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016. link
17. Regeneron. EYLEA HD (aflibercept) injection 8 mg prescribing information. Label effective April 6, 2026. link
18. Outlook Therapeutics. LYTENAVA (bevacizumab-vikg) injection prescribing information. Label effective September 3, 2026. link
19. ClinicalTrials.gov records NCT04704921 (ATMOSPHERE), NCT05407636 (ASCENT), NCT06864988 (4FRONT-1), NCT07064759 (4FRONT-2), NCT06856577 (ARTEMIS), NCT07482176 (AQUARIUS), NCT06223958 (SOL-1), NCT06495918 (SOL-R), NCT06556368 (DAYBREAK), NCT04757610 (ShORe), NCT04757636 (COAST), NCT07811726 (NT-101), NCT07607561 (SCAI-005), NCT07766473 (BETA-TT8). Checked October 20, 2026. NCT04704921 · NCT05407636 · NCT06864988 · NCT07064759 · NCT06856577 · NCT07482176 · NCT06223958 · NCT06495918 · NCT06556368 · NCT04757610 · NCT04757636 · NCT07811726 · NCT07607561 · NCT07766473
20. Spaide RF, et al. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020. link
21. Christakis PG, et al. Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study Report 40. Ophthalmology. 2020. link
22. Grunwald JE, et al. Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2017. link
23. Jeong YD, et al. Global burden of age-related macular degeneration, with forecast up to 2050: a modelling study. Ophthalmol Retina. 2026. link
24. Aslanis S, et al. Recurrent Neovascular Age-Related Macular Degeneration after Discontinuation of Vascular Endothelial Growth Factor Inhibitors Managed in a Treat-and-Extend Regimen. Ophthalmol Retina. 2022. link
25. Muether PS, et al. Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefes Arch Clin Exp Ophthalmol. 2011. link
26. Thornton J, et al. Smoking and age-related macular degeneration: a review of association. Eye (Lond). 2005. link
27. Khan JC, et al. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol. 2006. link
28. Vittorio AF, et al. SMOKING STATUS AND TREATMENT OUTCOMES OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2020. link
29. Seddon JM, et al. Familial aggregation of age-related maculopathy. Am J Ophthalmol. 1997. link
30. Jabbarpoor Bonyadi MH, et al. Comparison of ARMS2/LOC387715 A69S and CFH Y402H risk effect in wet-type age-related macular degeneration: a meta-analysis. Int Ophthalmol. 2019. link
31. National Eye Institute. AREDS/AREDS2 Frequently Asked Questions. Updated November 19, 2020. link
32. Clemons TE, et al. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology. 2005. link
33. Chakravarthy U, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010. link
34. Keenan TD, et al. Adherence to the Mediterranean Diet and Progression to Late Age-Related Macular Degeneration in the Age-Related Eye Disease Studies 1 and 2. Ophthalmology. 2020. link
35. Ferris FL, et al. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol. 2005. link
36. Maguire MG, et al. Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013. link
37. Fasler K, et al. Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration. Br J Ophthalmol. 2020. link
38. Cheung CMG, et al. Polypoidal Choroidal Vasculopathy: Consensus Nomenclature and Non-Indocyanine Green Angiograph Diagnostic Criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup. Ophthalmology. 2021. link
39. Chen CX, et al. Diagnostic Value of Optical Coherence Tomography Angiography for Choroidal Neovascularization in Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. Ophthalmic Res. 2021. link
40. Fine SL. Early detection of extrafoveal neovascular membranes by daily central field evaluation. Ophthalmology. 1985. link
41. AREDS2-HOME Study Research Group; Chew EY, et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization: home monitoring of the Eye (HOME) study. Ophthalmology. 2014. link
42. Bjerager J, et al. Diagnostic Accuracy of the Amsler Grid Test for Detecting Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2023. link
43. U.S. Food and Drug Administration, via openFDA. Device records: 510(k) K091579 (ForeseeHome), K050350 (Preview PHP), K014044 (MCPT), K180895 (Alleye), K121738 and K143211 (myVisionTrack); De Novo DEN230043 (Notal Vision Home OCT System) and DEN230083 (Valeda Light Delivery System); product classifications SAX, HPT and SDE. Checked October 19, 2026. link 1 · link 2 · link 3
44. U.S. Food and Drug Administration. De Novo DEN230043: Notal Vision Home Optical Coherence Tomography (OCT) System, granted May 15, 2024 (decision summary and openFDA record). summary · openFDA
45. Rifkin L, Schaal S. Factors affecting patients' pain intensity during in office intravitreal injection procedure. Retina. 2012. link
46. U.S. Food and Drug Administration, via openFDA. Drugs@FDA approval records: Lucentis (BLA125156), Eylea (BLA125387), Eylea HD (BLA761355), Beovu (BLA761125), Vabysmo (BLA761235), Susvimo (BLA761197), Lytenava (BLA761320), Visudyne (NDA021119), Macugen (NDA021756), Byooviz (BLA761202), Cimerli (BLA761165), Nufymco (BLA761473), Ranluspec (BLA761480), Yesafili (BLA761274), Opuviz (BLA761350), Ahzantive (BLA761378), Enzeevu (BLA761382), Pavblu (BLA761298) and Eydenzelt (BLA761377). Checked October 19, 2026. link
47. Genentech. LUCENTIS (ranibizumab injection) prescribing information. Label effective November 21, 2025. link
48. Regeneron. EYLEA (aflibercept) injection prescribing information. Label effective July 7, 2026. link
49. Novartis. BEOVU (brolucizumab-dbll) injection prescribing information. Label effective November 3, 2025. link
50. Genentech. SUSVIMO (ranibizumab injection) 100 mg/mL prescribing information. Label effective November 21, 2025. link
51. U.S. Food and Drug Administration, via openFDA. Drug enforcement report D-0025-2023: voluntary recall of the Susvimo ocular implant, initiated October 18, 2022, terminated April 17, 2024. Checked October 20, 2026. link
52. Ophthalmology Times. Genentech receives FDA approval to relaunch Susvimo. July 8, 2024. link
53. Genentech. VABYSMO (faricimab-svoa) injection prescribing information. Label effective April 15, 2026. link
54. Outlook Therapeutics. Outlook Therapeutics Announces LYTENAVA FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD (press release, via Finviz, July 24, 2026) and Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA (bevacizumab-vikg) (press release, via Finviz, October 1, 2026). link 1 · link 2
55. Sunaga T, et al. Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2024. link
56. Rao P, et al. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry. Ophthalmology. 2018. link
57. CATT Research Group; Martin DF, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011. link
58. Chakravarthy U, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013. link
59. Moja L, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014. link
60. Heier JS, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012. link
61. Dugel PU, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020. link
62. Heier JS, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022. link
63. Lanzetta P, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024. link
64. Khanani AM, et al. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology. 2024. link
65. Li E, et al. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020. link
66. CATT Research Group; Martin DF, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012. link
67. Wykoff CC, et al. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. Ophthalmology. 2015. link
68. Ciulla TA, et al. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes. Ophthalmol Retina. 2020. link
69. Chandra S, et al. Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration. Eye (Lond). 2020. link
70. Gillies M, et al. Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions. Am J Ophthalmol. 2020. link
71. Spooner K, et al. Long-term Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study: Report 1: Ten-Year, Real-World Outcomes. Ophthalmol Retina. 2021. link
72. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011. link
73. Zhang YS, et al. Comparative Endophthalmitis Rates of Anti-VEGF, Corticosteroid Implants and Anti-Complement Injections: An IRIS Registry Analysis. Am J Ophthalmol. 2026. link
74. Storey PP, et al. Rhegmatogenous Retinal Detachment after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor. Ophthalmology. 2019. link
75. Monés J, et al. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. Ophthalmology. 2021. link
76. Khanani AM, et al. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2022. link
77. Horn W, Hoerauf H. [Intravitreal injections during anticoagulant treatment]. Klin Monbl Augenheilkd. 2008. link
78. Bausch Health US. VISUDYNE (verteporfin for injection) prescribing information. Label effective August 27, 2025. link
79. Lim TH, et al. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial. JAMA Ophthalmol. 2020. link
80. Lee WK, et al. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. JAMA Ophthalmol. 2018. link
81. Gabrielle PH, et al. Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents, and Age-Related Macular Degeneration Study: A Randomized Controlled Trial for Submacular Hemorrhage Secondary to Age-Related Macular Degeneration. Ophthalmology. 2023. link
82. Jackson TL, et al. Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial. Trials. 2022. link
83. Weber C, et al. Antiplatelet and anticoagulant therapy in patients with submacular hemorrhage caused by neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023. link
84. National Eye Institute. AREDS 2 Supplements for Age-Related Macular Degeneration (AMD). Updated June 22, 2021. link
85. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001. link
86. Chew EY, et al. Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. JAMA Ophthalmol. 2022. link
87. Stelmack JA, et al. Outcomes of the Veterans Affairs Low Vision Intervention Trial (LOVIT). Arch Ophthalmol. 2008. link
88. Stelmack JA, et al. Outcomes of the Veterans Affairs Low Vision Intervention Trial II (LOVIT II): A Randomized Clinical Trial. JAMA Ophthalmol. 2017. link
89. Soares RR, et al. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor. Ophthalmol Retina. 2020. link
90. Goncalves L, et al. Outcomes in Neovascular Age-Related Macular Degeneration with Visit Gaps under Anti-VEGF Therapy in Daily Practice: Data from the Fight Retinal Blindness! Registry. Ophthalmol Retina. 2026. link
91. Obeid A, et al. Loss to Follow-up Among Patients With Neovascular Age-Related Macular Degeneration Who Received Intravitreal Anti-Vascular Endothelial Growth Factor Injections. JAMA Ophthalmol. 2018. link
92. Kodiak Sciences. Zenkuda and Tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria (press release). September 28, 2026. link
93. Ocular Therapeutix. Ocular Therapeutix Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD (press release, via Finviz, February 17, 2026); Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD (press release, via Finviz, April 13, 2026); Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights (press release, via Finviz, August 3, 2026); and Ocular Therapeutix Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI in Wet AMD (press release, via Finviz, September 15, 2026). link 1 · link 2 · link 3 · link 4
94. REGENXBIO. REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting (press release, July 18, 2026); REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights (press release, August 6, 2026); and REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 (press release, October 12, 2026). link 1 · link 2 · link 3
95. 4D Molecular Therapeutics. 4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD (press release, via Finviz, June 29, 2026); 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population (press release, via Finviz, July 18, 2026); 4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones (press release, via Finviz, August 13, 2026); and 4DMT to Host Investor Day on October 21, 2026 (press release, via Finviz, October 5, 2026). link 1 · link 2 · link 3 · link 4
96. Eli Lilly and Company. Lilly and Adverum Announce Expiration and Completion of Adverum Tender Offer and Acquisition (press release). December 9, 2025. link
97. EyePoint. EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU 2.7mg in Wet AMD (press release, via Finviz, August 17, 2026); EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU in Wet AMD (press release, via Finviz, October 19, 2026); and EyePoint Announces Strategic Prioritization (press release, via Finviz, October 19, 2026). link 1 · link 2 · link 3
98. Mayo Clinic. Wet macular degeneration: symptoms and causes; diagnosis and treatment. December 11, 2024. link 1 · link 2
99. National Center for Complementary and Integrative Health. Ginkgo: Usefulness and Safety. Updated February 2025. link
100. National Center for Complementary and Integrative Health. Turmeric: Usefulness and Safety. Updated April 2025. link
101. Sun W, et al. Effects of acupuncture on age-related macular degeneration: A systematic review and meta-analysis of randomized controlled trials. PLoS One. 2023. link
102. PubMed, Europe PMC and ClinicalTrials.gov searches for acupuncture, Chinese herbal medicine, Ayurveda, saffron, curcumin, omega-3, lutein, smoking, exercise, anticoagulants and mortality in wet AMD. Run October 19, 2026. PubMed · Europe PMC · ClinicalTrials.gov
103. Chen KY, et al. Is acupuncture a viable therapeutic strategy for degenerative eye diseases? a systematic review and meta-analysis. Complement Ther Med. 2025. link
104. Bautista-Hernández MA, et al. Acupuncture in the treatment of inflammation-related ocular degenerations: a systematic review. Front Med (Lausanne). 2026. link
105. Jin M, et al. A Traditional Chinese Patent Medicine ZQMT for Neovascular Age- Related Macular Degeneration: A Multicenter Randomized Clinical Trial. Curr Mol Med. 2018. link
106. Pan HT, et al. Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration. J Int Med Res. 2020. link
107. Lashay A, et al. Short-term Outcomes of Saffron Supplementation in Patients with Age-related Macular Degeneration: A Double-blind, Placebo-controlled, Randomized Trial. Med Hypothesis Discov Innov Ophthalmol. 2016. link
108. Allegrini D, et al. Curcuma-Based Nutritional Supplement in Patients with Neovascular Age-Related Macular Degeneration. J Med Food. 2021. link
109. Semeraro F, et al. Treatment of exudative age-related macular degeneration with aflibercept combined with pranoprofen eye drops or nutraceutical support with omega-3: A randomized trial. Br J Clin Pharmacol. 2019. link
110. Rezende FA, et al. Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration. Am J Ophthalmol. 2014. link
111. U.S. Food and Drug Administration. De Novo DEN230083: Valeda Light Delivery System, granted November 4, 2024 (decision summary and openFDA record); and ClinicalTrials.gov NCT04065490 (LIGHTSITE III) results. summary · openFDA · NCT04065490
112. Lee SM, et al. Severe Adverse Events of Periocular Acupuncture: A Review of Cases. Korean J Ophthalmol. 2023. link
113. Bloch SB, et al. Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. Am J Ophthalmol. 2012. link
114. Keenan TD, et al. Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19. Ophthalmol Retina. 2020. link
115. McGuinness MB, et al. Age-Related Macular Degeneration and Mortality: A Systematic Review and Meta-Analysis. Ophthalmic Epidemiol. 2017. link
116. AREDS2 Research Group; Papudesu C, et al. Association of mortality with ocular diseases and visual impairment in the Age-Related Eye Disease Study 2: AREDS2 report number 13. Ophthalmology. 2018. link
117. Thinggaard BS, et al. VEGF Inhibition Associates With Decreased Risk of Mortality in Patients With Neovascular Age-related Macular Degeneration. Ophthalmol Sci. 2024. link